Spots Global Cancer Trial Database for metastatic cervical cancer
Every month we try and update this database with for metastatic cervical cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer | NCT03367871 | Cervical Cancer | Pembrolizumab Paclitaxel Cisplatin Carboplatin Bevacizumab | 18 Years - | University of Miami | |
| Safety of Effivia®, a Bevacizumab Biosimilar | NCT06313268 | Metastatic Colo... Metastatic Cerv... Non Squamous No... | Bevacizumab Bio... | 18 Years - | Laboratorios Liomont | |
| Dostarlimab and Cobolimab in Advanced Cervical Cancer | NCT06238635 | Cervical Cancer Advanced Cervic... Metastatic Cerv... Metastatic Cerv... Recurrent Cervi... | Dostarlimab Cobolimab | 18 Years - | Beth Israel Deaconess Medical Center | |
| Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer | NCT04230954 | Cervical Cancer Recurrent Cervi... Metastatic Cerv... Persistent Cerv... | Cabozantinib 40... Pembrolizumab 2... | 18 Years - | University of South Alabama | |
| Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy | NCT05614453 | Metastatic Cerv... | Tislelizumab Sitravatinib | 18 Years - | Australia New Zealand Gynaecological Oncology Group | |
| Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers | NCT00319748 | Breast Cancer Ovarian Cancer Endometrial Can... Cervical Cancer | 852A | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) | NCT04943627 | Advanced Cancer Metastatic Cerv... | Balstilimab (BA... Topotecan Vinorelbine Gemcitabine Irinotecan Pemetrexed | 18 Years - | Agenus Inc. | |
| Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer | NCT03277482 | Recurrent Gynec... Metastatic Cerv... Metastatic Ovar... Metastatic Vagi... Metastatic Vulv... Metastatic Endo... Recurrent Cervi... Recurrent Ovari... Recurrent Vagin... Recurrent Vulva... Recurrent Endom... | Durvalumab Tremelimumab Radiation Thera... | 18 Years - | Dana-Farber Cancer Institute | |
| Dostarlimab and Cobolimab in Advanced Cervical Cancer | NCT06238635 | Cervical Cancer Advanced Cervic... Metastatic Cerv... Metastatic Cerv... Recurrent Cervi... | Dostarlimab Cobolimab | 18 Years - | Beth Israel Deaconess Medical Center | |
| A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer | NCT04380805 | Recurrent Cervi... Metastatic Cerv... | AK104 | 18 Years - | Akeso | |
| Hydralazine Valproate for Cervical Cancer | NCT00532818 | Metastatic Cerv... | Hydralazine and... Placebo | 18 Years - | National Institute of Cancerología | |
| Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers | NCT00319748 | Breast Cancer Ovarian Cancer Endometrial Can... Cervical Cancer | 852A | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Safety of Effivia®, a Bevacizumab Biosimilar | NCT06313268 | Metastatic Colo... Metastatic Cerv... Non Squamous No... | Bevacizumab Bio... | 18 Years - | Laboratorios Liomont | |
| Safety of Effivia®, a Bevacizumab Biosimilar | NCT06313268 | Metastatic Colo... Metastatic Cerv... Non Squamous No... | Bevacizumab Bio... | 18 Years - | Laboratorios Liomont | |
| Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer | NCT03367871 | Cervical Cancer | Pembrolizumab Paclitaxel Cisplatin Carboplatin Bevacizumab | 18 Years - | University of Miami | |
| Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer | NCT00106262 | Cervical Cancer | Velcade (bortez... Irinotecan | 18 Years - 80 Years | Women and Infants Hospital of Rhode Island | |
| Self-Hypnosis for the Enhanced Recovery After Surgery in Patients With Gynecologic Cancer | NCT04266886 | Malignant Femal... Recurrent Malig... Metastatic Cerv... | Best Practice Hypnotherapy Quality-of-Life... Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| Hydralazine Valproate for Cervical Cancer | NCT00532818 | Metastatic Cerv... | Hydralazine and... Placebo | 18 Years - | National Institute of Cancerología |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
